JPMorgan analyst Cory Kasimov sees "potential for significant upside" in shares of BioMarin following the 29% year-to-date pullback. Data readouts in the next few months could serve as positive catalysts, Kasimov tells investors in a research note. The analyst believes pegvaliase's Phase 3 trial in phenylketonuria should be one of the first data readouts, and he anticipates positive results. Kasimov lowered his price target for BioMarin to $121 from $141 and keeps an Overweight rating on the name. The drugmaker closed yesterday down $2.94 to $74.87.